{
  "docId": "019de075-5375-74ac-b63e-223f7dcbcdee",
  "docSlug": "1e5a737805b52115da5825472ef93325",
  "documentTitle": "Hillstream BioPharma | Investor Presentation Deck | 19 slides",
  "authorId": "hillstream-biopharma",
  "authorName": "Hillstream BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 19,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a visual representation of an ADC molecule to explain the components and the therapeutic mechanism.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5375-74ac-b63e-223f7dcbcdee/12",
  "deckHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee",
  "deckJsonHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee.json",
  "deckAnchorHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "image",
      "text": "Diagram of an antibody-drug conjugate molecule",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34c9d542-e85b-4db1-81f0-b506f24daf86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.5,
        "x": 0.414,
        "y": 0.178
      },
      "kind": "list",
      "text": "Antibody Drug Conjugates (ADCs) are: 1) a cancer killing chemotherapeutic payload, 2) an antibody-targeting a cancer cell, 3) a linker connecting the antibody to the payload",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96ec3583-29fe-46f8-88f3-36fc8910c67c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.414,
        "y": 0.375
      },
      "kind": "paragraph",
      "text": "Problem: ADCs targeting HER2 and/or HER3 essentially target same epitopes as trastuzumab based domains",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f8a19f3-14e8-469e-9d5e-c94044526ba8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.414,
        "y": 0.73
      },
      "kind": "paragraph",
      "text": "Bystander effect: Toxin delivered to surrounding non-antigenic cancer tissue; HSB-0059 capitalizes on emerging evidence of effect independent of internalization and designed to maximize this effect",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9368fd6a-91c3-4f05-a8cb-dd0fe320c7b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.414,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "Our solution: Based on data from HSB-3215 (HER2/HER3) mAb, HSB-0059 targets novel epitopes on HER2 while preventing heterodimers to HER3 with potential bystander effect of toxin payload",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "963cd8b9-891b-45a5-b892-cf23417bc0ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "HSB-0059: Anti-HER2/HER3 BSp Antibody-drug Conjugate",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b2ccba6-c71e-4b74-ab1a-7566f015c244",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 4,
      "beatId": "e53add27-632d-4b4f-baf0-308f53797da9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-14 present the company's solution, including the lead program HSB-3215 and its technical advantages",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}